Ones To Watch News
Refine Search
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Privately-held Dutch biotech Amarna Therapeutics has appointed Dr Henk Streefkerk as the company’s new chief executive and medical director. 7 June 2023
Biotechnology
Flagship Pioneering founded company Ring Therapeutics today announced the appointment of Konstantin Konstantinov as its chief technology officer. 7 June 2023
Pharmaceutical
USA-based Paratek Pharmaceuticals saw its shares leap almost 14% to $2.22 by mid-morning today, after it revealed it has entered into a definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings. 6 June 2023
Biotechnology
Shares of US firm Ultragenyx Pharmaceutical and UK-based Mereo BioPharma rose in pre-market activity, up 6.5% to $54.48 and 11.4% at $1.17, respectively, after the companies released new showing that setrusumab rapidly induced bone production in osteogenesis imperfecta (OI)-affected patients. 6 June 2023
Biotechnology
German CAR-T cell therapy specialist T-CURX has announced two appointments to its senior leadership team. 6 June 2023
Biotechnology
Along with the big pharma players showing off the potential of their cancer drugs at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), biotech companies have been making their presence felt, too. 5 June 2023
Biotechnology
Data presented at the American Society of Clinical Oncology (ASCO) reinforce enthusiasm for a new approach being developed by companies including Elevation Oncology. 5 June 2023
Pharmaceutical
More than three dozen state-level enforcers reached a $102.5 million deal with Indivior to resolve claims that the drugmaker monopolized the market for the opioid addiction treatment Suboxone (buprenorphine) ahead of a looming September trial. 5 June 2023
Biotechnology
Building on the extraordinary success of its platform in producing an effective coronavirus vaccine, German mRNA specialist BioNTech is making inroads on a project which broadens its focus to include checkpoint inhibition. 2 June 2023
Biosimilars
US biosimilars developer Coherus BioSciences saw its share rise 5% to $4.05 pre-market, after it announced it will launch Yusimry (adalimumab-aqvh) next month. 2 June 2023
Biotechnology
Phase II results from Austrian arenaviral technology firm Hookipa Pharma show a 43% objective response rate (ORR) for its lead candidate in head and neck cancer. 2 June 2023
Biotechnology
California, USA-based biotech start-up Eikon Therapeutics has acquired exclusive rights to multiple early- to mid-stage assets, leveraging its proprietary Single Molecule Tracking (SMT) technology to drive strategic decisions around its new drug pipeline. 2 June 2023
Biotechnology
Swiss contract development and manufacturing organization (CDMO) Lonza today announced it has acquired Dutch biotech company Synaffix, which is focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugate (ADCs). 1 June 2023
Pharmaceutical
Swedish immunology company InDex Pharmaceuticals InDex Pharmaceuticals has signed a license agreement with the Japanese subsidiary of Viatris to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. 1 June 2023
Pharmaceutical
Shares of US biotech Amylyx Pharmaceuticals fell more than 3% by close of trading Tuesday and a further 2.2% to $23.51 in pre-market activity today, after it said that a European regulatory panel had taken a negative view on its amyotrophic lateral sclerosis (ALS) treatment 31 May 2023
Pharmaceutical
Chinese artificial intelligence company XtalPi has agreed terms for a $250 million collaboration with Eli Lilly. 31 May 2023
Biotechnology
Swiss biotech Idorsia today revealed that Simon Jose will leave his position as chief commercial officer and member of the Idorsia executive committee to pursue other opportunities. 30 May 2023
Pharmaceutical
Privately-held Italian drugmaker Menarini has announced results from a new analysis of the pivotal EMERALD clinical study that suggest that oral single-agent Orserdu (elacestrant) may be effective in ER+, HER2- advanced or metastatic breast cancer patients with non-detected ESR1-mut whose disease has progressed within six months of treatment with a CDK4/6i. 30 May 2023
Pharmaceutical
The US Food and Drug Administration (FDA) on Friday approved Inpefa (sotagliflozin), developed by Lexicon Pharmaceuticals. 27 May 2023
Biotechnology
US clinical-stage biotech Carmot Therapeutics has announced a $150 million oversubscribed and up-sized Series E financing. 27 May 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze